Molecular Templates, Inc. (MTEM )

Currency in USD Disclaimer
$0.16 -$0.19 (-54.67%)
Closed 12/20/2024
$0.14
$0.18
$0.14
$4.12

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol MTEM
  • Company Molecular Templates, Inc.
  • Price $0.16
  • Changes Percentage -54.67
  • Change -0.193
  • Day Low $0.14
  • Day High $0.18
  • Year High $4.12
  • Year Low $0.14
  • Market Cap $1,053,421
  • Price Avg 50 EMA (D) $0.49
  • Price Avg 200 EMA (D) $1.28
  • Exchange NASDAQ
  • Volume 8,357,289
  • Average Volume 14,785,317
  • Open $0.15
  • Previous Close $0.35
  • EPS -3.05
  • PE -0.05
  • Earnings Announcement 2024-12-19 10:59:00
  • Shares Outstanding $6,583,880

Company brief: MOLECULAR TEMPLATES, INC. (MTEM )

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

MTEM Corporation News

Income Statement